Copyright
©The Author(s) 2016.
World J Diabetes. Nov 15, 2016; 7(19): 534-546
Published online Nov 15, 2016. doi: 10.4239/wjd.v7.i19.534
Published online Nov 15, 2016. doi: 10.4239/wjd.v7.i19.534
Figure 14 The area of immunohistochemical staining for lymphatic vessel endothelial hyaluronan receptor-1 in the liver of intact, placebo-treated and linagliptin-treated db/db mice.
aP < 0.05 vs control group (intact animals); cP < 0.05 vs placebo group. pix sq: Square pixel.
- Citation: Michurina SV, Ishenko IJ, Klimontov VV, Archipov SA, Myakina NE, Cherepanova MA, Zavjalov EL, Koncevaya GV, Konenkov VI. Linagliptin alleviates fatty liver disease in diabetic db/db mice. World J Diabetes 2016; 7(19): 534-546
- URL: https://www.wjgnet.com/1948-9358/full/v7/i19/534.htm
- DOI: https://dx.doi.org/10.4239/wjd.v7.i19.534